REMINDER: Shifting Landscape in Biotech Venture Capital - 12/8 at 6:30pm at HMS

[Vincent Chan]

*[image: Inline image 1]*

*The Biotech Connection in Boston (BCB) presents:*



Shifting Landscape in Biotech Venture Capital:

Rise in Alternative Funding



*Monday, December 8th, 2014*

*6:30 pm – Carl W. Walter Amphitheatre, Harvard Medical School*



Register for *FREE* at

http://www.eventbrite.com/e/shifting-landscape-in-biotech-venture-capital-registration-13803118499



*Panelists:*

*Deborah W. Brooks*, Michael J. Fox Foundation, *Co-Founder & Executive
Vice Chairman, *
*Adam Griff*, MedStartr, *Chief Operating Officer*

*Imran Nasrullah*, Boehringer Ingelheim, *Director of Innovation Sourcing*
*Rajeev Shah*, RA Capital, *Managing Partner*
*Christopher De Souza*, Broadview Ventures, *Director*



*Abstract:*

After the 2008 and 2011 economic downturns, the funding landscape in the
life sciences began to shift dramatically. A majority of traditional
venture capital firms in the life sciences moved away from high risk, early
stage investments and opted for less risky, more developed investments or
creating companies in-house using their internal networks. As a result,
there has been a drop off in first-round funding placed into life sciences
companies from 23% in 2006 down to 12.8% in 2012.



Despite a handful of firms that continue to build companies from scratch,
strategic changes from traditional VC firms have created a large funding
gap that will be a challenge for new bioentrepreneurs to overcome.
Fortunately, there are a number of alternative funds filling in the void
that traditional VC firms have created. Big pharma and biotech companies
are creating their own corporate venture funds and incubators to directly
invest in earlier stage development as a viable alternative to traditional
in-house R&D. A new wave of foundations, nonprofits, and venture
philanthropists are partnering with commercial biotech companies to fill
the need of early-stage investments. Furthermore, with the advent of the
JOBS Act and emergence of credible platforms, angel networks have expanded
to include crowdfunding as a meaningful way to obtain early stage funds in
biotech.



Undoubtedly, these strategic shifts by traditional and corporate VC firms,
along with increased alternative funding in early stage ventures with an
eye towards commercialization, are set to have a significant impact on
bioentrepreneurship. With an increasing number of investors at each stage,
it is likely that a single venture may be funded by several sources along
the path from inception to exit. Having a plethora of options is certainly
exciting but investors will have to work together in a cohesive, structured
manner in order for individual entrepreneurs, and the biotech industry as a
whole, to fully realize the benefits of having such a wide array of funding
opportunities. For each new venture, the new challenge is to find ways to
efficiently and effectively utilize these many different funding platforms,
each with its own strategy and philosophy. How will these new funding
sources cooperate and interface with more traditional sources to fund the
latest advances in the life sciences sector?


Please join us for the Biotech Connection’s launch event in Boston
examining the shifting funding landscape in the biotech industry from the
perspective of leading experts. It brings together industry leaders from a
traditional venture capital firm to alternative sources, such as a
corporate venture fund, family office, foundation, and a new crowdsourcing
platform.



*Program:*

6:00PM – Registration begins
6:30PM – Opening remarks
6:40PM – Panel discussion with Q&A
7:30PM – Networking reception with light refreshments



*Sponsors:*
[image: Inline image 4]  [image: Inline image 5]  [image: Inline image
2]  [image:
Inline image 1]

*----------------------------------------------------------------------------*

*For more information: chanv at mit.edu <chanv at mit.edu>*

*Join BCB: **http://www.bostonbiotech.org/ <http://www.bostonbiotech.org/>*

*Follow us on Twitter: **@BioConBoston <https://twitter.com/BioConBoston>*
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0001.htm
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image.png
Type: image/png
Size: 14163 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0005.png
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image.png
Type: image/png
Size: 9915 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0006.png
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image.png
Type: image/png
Size: 12316 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0007.png
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image.png
Type: image/png
Size: 3956 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0008.png
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image.png
Type: image/png
Size: 6024 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0009.png
-------------- next part --------------
A non-text attachment was scrubbed...
Name: BCB Launch Flyer.pdf
Type: application/pdf
Size: 303909 bytes
Desc: not available
Url : http://mailman.mit.edu/pipermail/mit-postdocs/attachments/20141124/8c463dda/attachment-0001.pdf